Despite an Overall Sour VC Market, Genomics Start Ups Saw More Cash in Q1 | GenomeWeb

NEW YORK, March 29 - Early-stage biotech companies, including genomic tool and technology firms, are enjoying the best venture-capital market in a decade, according to results of a recent market study.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.